Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib
The 3rd class of BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) variants including G466, D594,...
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (...
Introduction BRAF V600 E mutations have been identified in a subset of patients with primary brain t...
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refract...
International audienceMultiple myeloma (MM) is still considered incurable and new therapeutic approa...
Vemurafenib and dabrafenib, two potent tyrosine kinase inhibitors (TKIs) of the BRAF(V600E) kinase, ...
Combined MEK‐BRAF inhibition is a well‐established treatment strategy in BRAF‐mutated cancer, most p...
Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and...
We present 8-year follow-up on the first patient with stage 4 ameloblastoma carrying a BRAF V600E mu...
The management of cancer has been traditionally dependent on the primary tumour type and specific hi...
Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the...
Abstract Background Targeting ...
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and...
Since 2011, the treatment options for metastatic malignant melanoma have significantly changed. In t...
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (...
The 3rd class of BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) variants including G466, D594,...
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (...
Introduction BRAF V600 E mutations have been identified in a subset of patients with primary brain t...
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refract...
International audienceMultiple myeloma (MM) is still considered incurable and new therapeutic approa...
Vemurafenib and dabrafenib, two potent tyrosine kinase inhibitors (TKIs) of the BRAF(V600E) kinase, ...
Combined MEK‐BRAF inhibition is a well‐established treatment strategy in BRAF‐mutated cancer, most p...
Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and...
We present 8-year follow-up on the first patient with stage 4 ameloblastoma carrying a BRAF V600E mu...
The management of cancer has been traditionally dependent on the primary tumour type and specific hi...
Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the...
Abstract Background Targeting ...
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and...
Since 2011, the treatment options for metastatic malignant melanoma have significantly changed. In t...
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (...
The 3rd class of BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) variants including G466, D594,...
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (...
Introduction BRAF V600 E mutations have been identified in a subset of patients with primary brain t...